Evaluating heart failure with preserved ejection fraction using advanced imaging techniques
Multimodality Imaging (Cardiovascular Magnetic Resonance Imaging, Echocardiography, and Nuclear Medicine Imaging) in the Screening, Diagnosis and Risk Stratification of Heart Failure With Preserved Ejection Fraction- a Multicenter Study.
Chinese Academy of Medical Sciences, Fuwai Hospital · NCT04602338
This study is trying to see if advanced imaging techniques can help doctors better understand and diagnose heart failure with preserved ejection fraction in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT04602338 on ClinicalTrials.gov |
What this trial studies
This study investigates heart failure with preserved ejection fraction (HFpEF) by utilizing multimodality imaging techniques, including cardiovascular magnetic resonance imaging, echocardiography, and nuclear medicine imaging. It aims to identify cardiac features, early diagnosis, and risk factors associated with HFpEF in a multicenter population. The study combines large data analysis and artificial intelligence to enhance understanding of this condition, which is often underdiagnosed and misunderstood. By focusing on early identification and intervention, the research seeks to improve patient outcomes and quality of life.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with heart failure symptoms and preserved left ventricular ejection fraction (LVEF ≥ 50%).
Not a fit: Patients with specific types of cardiomyopathy, severe arrhythmias, or significant valvular disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better management of heart failure with preserved ejection fraction, ultimately improving patient outcomes.
How similar studies have performed: Other studies have explored similar imaging approaches for heart failure, indicating potential for success in understanding and diagnosing HFpEF.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * left ventricular ejection fraction (LVEF)≥50%； * N-terminal pro-b type natriuretic peptide (NT-proBNP)\>220pg/ml or b type natriuretic peptide (BNP) \>80 pg/ml; * symptoms and syndromes of heart failure; * At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler). Exclusion Criteria: * Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc. * Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ; * Severe arrhythmia; * Severe primary cardiac valvular disease; * Restrictive pericardial disease; * Refuse to participate in the study.
Where this trial is running
Beijing, Beijing Municipality
- Fuwai Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Minjie Lu, PhD
- Email: coolkan@163.com
- Phone: 86 10 88396941
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Heart Failure, Diastolic, Multicenter Study, heart failure with preserved ejection fraction, cardiovascular magnetic resonance imaging, echocardiography, nuclear medicine imaging, early diagnosis, prognosis